bioporto
DIAGNOSTICS

Empowering Early Detection of Kidney Injury

Rights Offering

May 31, 2023

Forward-Looking Statements

References herein to this presentation shall mean and include this document, any oral presentation accompanying this document provided by BioPorto A/S (the "Company" or "BioPorto"), and any further information that may be made available in connection with the subject matter contained herein. By viewing, receiving or reading this presentation or attending any meeting where this presentation is made, you agree to be bound by the limitations, qualifications and restrictions set out below.

This presentation contains forward-looking statements. Words such as "believe", "expect", "may", "plan", "strategy", "estimate", "target" and similar expressions identify such forward-looking statements. Statements other than historical facts included in this presentation concerning our plans, objectives, goals, future events and performance are forward-looking statements. They involve risks, uncertainties and other factors, which may cause actual results, performance and achievements to differ materially from those contained in the forward-looking statements. These include numerous assumptions, risks and uncertainties, many of which are beyond BioPorto's control. These assumptions, risks and uncertainties are described from time to time in BioPorto's public announcements, its Interim Reports, and in its 2022 Annual Report under Risk Factors. BioPorto undertakes no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date of this presentation, except as required by applicable law.

THIS PRESENTATION IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS PRESENTATION IS FOR INFORMATION PURPOSES ONLY AND DOES NOT CONSTITUTE AN OFFER TO SELL OR ISSUE, OR A SOLICITATION OF AN OFFER TO BUY, SUBSCRIBE FOR OR OTHERWISE ACQUIRE ANY SECURITIES IN THE UNITED STATES (INCLUDING ITS TERRITORIES AND POSSESSIONS, ANY STATE OF THE UNITED STATES AND THE DISTRICT OF COLUMBIA (COLLECTIVELY, THE "UNITED STATES")) OR ANY OTHER JURISDICTION IN WHICH SUCH OFFER OR SOLICITATION WOULD BE UNLAWFUL OR TO ANY PERSON TO WHOM IT IS UNLAWFUL TO MAKE SUCH OFFER OR SOLICITATION.

THE SECURITIES REFERRED TO HEREIN HAVE NOT BEEN AND WILL NOT BE REGISTERED UNDER THE U.S. SECURITIES ACT OF 1933, AS AMENDED (THE "SECURITIES ACT"), AND MAY NOT BE OFFERED OR SOLD IN THE UNITED STATES, EXCEPT PURSUANT TO AN APPLICABLE EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN COMPLIANCE WITH ANY APPLICABLE SECURITIES LAWS OF ANY STATE OR OTHER JURISDICTION OF THE UNITED STATES, EXCEPT PURSUANT TO AN APPLICABLE EXEMPTION FROM THE REGISTRATION REQUIREMENTS AND IN COMPLIANCE WITH ANY APPLICABLE SECURITIES LAWS OF ANY SUCH STATE OR OTHER JURISDICTION (AS THE CASE MAY BE).

Today's Agenda

- Significant Clinical Impact of Acute Kidney Injury (AKI)
- FDA Submission Update
- Participating in the Rights Offering
- How to Exchange Rights into Shares
- Timeline
- Q&A

bioporto DIAGNOSTICS

Acute Kidney Injury (AKI) leads to poor outcomes if untreated

An abrupt loss of kidney function that develops rapidly over a few hours or days



- Cardiac Surgery
- Mechanical Ventilation
- Transplant
- Sepsis
- Nephrotoxic Agents



Sources: Silver SA, Chertow GM. The Economic Consequences of Acute Kidney Injury, Nephron. 2017;137.
A Multidisciplinary and International Assessment of Acute Kidney Injury Awareness, Ipsos MORI UK Ltd., May 25, 2022.

AKI - an unmet clinical need for early diagnosis

AKI is Common & Costly

- **1 in 5 adults**[1] and **1 in 4 children**[2]
- **13.3 million per year worldwide**[3]
- **+$7,000 per episode**[4]
- Costing the US healthcare system **$5.4 - $24.0 billion annually**[4]

Serum Creatinine

- **2-3 days delayed** response
- confounded by age, muscle mass, gender
- **27.8% AKI missed**[5]
- 66% of AKI misclassified[6]

Value of Early Identification

eAlert + biomarkers[7]

- higher rate of AKI **recovery** (+22%)
- more **RRT-free days**
- **shorter ICU stays**
- 33% **reduction in Stage 2/3 AKI**
- 50% **reduction in persistent AKI**
- initiates earlier **nephrology follow-up**

bioporto DIAGNOSTICS

1) Susantitaphong P. CJASN. 2014;9(6) | 2) Kaddourah A. N Engl J Med. 2017 | 3) Mehta RL. Lancet. 2015 | 4) Silver SA. Nephron. 2017;137 | 5) Stanski Journal of Critical Care. 2019;53:1-7 | 6) RIcci JCardiothVasc 2021 | 7) Halmy Journal of Clinical Medicine 2021.

US Market: Initial FDA Authorization for Pediatric Patients

We will establish a beachhead in the US market focused on testing pediatric patients

- Currently, 30+ US hospitals utilize the RUO NGAL test clinically as a Lab Developed Test (LDT)
- Achieved Breakthrough Status with the FDA due to the significant unmet need for pediatric patients
- Pediatric market has potential for more rapid adoption of breakthrough products to save the lives
- This beachhead will demonstrate the life and cost saving value of NGAL that is expected to enable rapid adoption for testing the Adult population market following FDA clearance

Rights offering of DKK 59.4M with Pre-Emptive Rights

DKK 16.6M (28%) is Already Subscribed

- Major shareholders
- Entire Board of Directors
- Management team members

Builds upon Cost Control and Working Capital Management Activities

All Shareholders Can Participate on the Same Terms

Rights offering of DKK 59.4M with Pre-Emptive Rights

DKK 16.6M (28%) is Already Subscribed

- Major shareholders
- Entire Board of Directors
- Management team members

Builds upon Cost Control and Working Capital Management Activities

All Shareholders Can Participate on the Same Terms

Proceeds Strengthen Capital Resources

- Advance implementation of strategic priorities:
  - Grow revenues in European and other markets that accept CE Mark
  - Support inquires from the US FDA regarding the De Novo Application
  - Expand the total addressable market for NGAL tests
  - General corporate purposes

How to Participate in the Offering at DKK 1.00/share

1. Exercise Rights

- Shareholders: contact your bank to exercise your pre-emptive rights
- Anyone: buy rights on the market & exercise them through your bank (ISIN DK0062496477)

2. Subscribe for any Remaining Shares[(a)]

- Anyone[(b)]: contact BioPorto for details (investor@bioporto.com)

(a) Remaining Shares are New Shares, if any, that have not been subscribed for by exercise of Pre-Emptive Rights during the Subscription Period. If Remaining Shares are oversubscribed, they will be allocated according to the Board of Directors' discretion.
(b) Available to eligible investors, subject to EU, Denmark, and other applicable laws & regulations.

bioporto DIAGNOSTICS

Targeted rights offering of DKK 59.4M
The exchange ratio is 3:17

Each holder of existing shares in BioPorto registered as such with Euronext Securities on May 31st

→

Will be allocated 3 Pre-Emptive Rights for each Existing Share held

→

17 Pre-Emptive Rights + DKK 1.00 Subscription Price = 1 New Share

Targeted rights offering of DKK 59.4M
The exchange ratio is 3:17

Each holder of existing shares in BioPorto registered as such with Euronext Securities on May 31st

→

Will be allocated 3 Pre-Emptive Rights for each Existing Share held

→

17 Pre-Emptive Rights + DKK 1.00 Subscription Price = 1 New Share

Example pre-emptive rights issue

51
Current Shares

→

153
Pre-emptive Rights

→

9
New Shares at DKK 1.00/share

bioporto DIAGNOSTICS

KEY DATES

Subscription Period

- First day: 6 June 2023
- Last day: 19 June 2023

Rights Trading Period

- First day: 1 June 2023
- Last day: 15 June 2023

Payment for New Shares must be made in DKK on the date of subscription and in no event later than June 19, 2023 at 17:00 CEST.

bioporto
DIAGNOSTICS

Thank you

CPH: BIOPOR

Contact: Tim Ericksen
Zenith Advisory
investor@bioporto.com